Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 9040050 Combination treatment of CD38-expressing tumors

Patent 9040050 was granted and assigned to Genmab A/S on May, 2015 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

0

Patent attributes

Current Assignee

0

Patent Jurisdiction

United States Patent and Trademark Office

0

Patent Number

Patent Inventor Names

Yvo Graus0

Jan Van De Winkel0

Judith Oprins0

Martine Van Vugt0

Michel De Weers0

Ole Baadsgaard0

Paul Parren0

Steen Lisby0

Date of Patent

May 26, 2015

0

Patent Application Number

124428080

Date Filed

September 26, 2007

0

Patent Citations Received

US Patent 12091466 Anti-CD38 antibodies for treatment of light chain amyloidosis and other CD38-positive hematological malignancies

0

US Patent 11708420 Subcutaneous formulations of anti-CD38 antibodies and their uses

0

US Patent 11708419 Subcutaneous formulations of anti-CD38 antibodies and their uses

0

US Patent 11713355 Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia

0

US Patent 12060432 Combination therapies with anti-CD38 antibodies

0

Patent Primary Examiner

0

Patent abstract

The invention relates to novel method for the treatment of cancer using a combination therapy comprising an antibody that binds CD38, a corticosteroid and a non-corticosteroid chemotherapeutic agent.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 9040050 Combination treatment of CD38-expressing tumors

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool

By using this site, you agree to our Terms of Service.